Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 12Completed 7Not yet recruiting 6Terminated 5Unknown 3Enrolling by invitation 1Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 9Specimen Handling 7Educational Status 7Standard of Care 6Interviews as Topic 6Drug Therapy 6Carboplatin 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Surveys and Questionnaires 4Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Observation 4Lenalidomide 4Fluorouracil 4Fluorodeoxyglucose F18 4Dexamethasone 4pembrolizumab 3lenvatinib 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Gemcitabine 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × trilaciclib × Clear all
NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Henan Cancer Hospital

Phase 2 Enrolling by invitation
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡